Study Summary
The study "GALAXY33" is an open-label, prospective, nonrandomized, one arm phase I clinical trial in which patients with relapsed AML after allogeneic hematopoietic stem cell transplantation will be transplanted with CD33-deleted CD34+ HSC derived from the initially matched family donor.
Want to learn more about this trial?
Request More InfoInterventions
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletionBIOLOGICAL
CD33-deleted CD34+ hematopoietic stem cells derived from the initially matched family donor
Gemtuzumab OzogamicinDRUG
Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University Hospital Dresden, Department of Medicine I | Dresden | Germany | |
| University Hospital Heidelberg, Internal Medicine V | Heidelberg | Germany |